Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings

Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target. The firm stated that Incyte’s povorcitinib could be administered in the early stages of hidradenitis suppurativa, rather than as a post-biologic oral alternative.

H.C. Wainwright mentioned a meeting with a hidradenitis suppurativa expert who oversees a clinic at Geisinger Health with about 700 patients rotating each year, with nearly 80% categorized as moderate to severe.

In a similar vein, Citizens JMP reaffirmed its Market Perform rating for Incyte Corporation (NASDAQ:INCY) following the presentation of revised clinical trial data at the AAD 2026 Congress. Incyte reported 54-week results from the Phase 3 STOP-HS1/HS2 studies, which evaluated povorcitinib in moderate-to-severe hidradenitis suppurativa.

The data demonstrated that effectiveness deepens gradually with increasing HiSCR50 rates in both the initial treatment and crossover groups. Citizens stated that it has grown more convinced that implementation across the current portfolio can overcome the $3 billion-plus ruxolitinib patent gap by the end of 2028.

Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.